ImmunityBio
NewsRecent Press Releases
ImmunityBio Granted FDA Breakthrough Therapy Designation for N-803 IL-15 Superanonist in Non-Muscle Invasive Bladder Cancer
Results of Phase 1 and 2 studies in BCG Unresponsive Non-Muscle Invasive Bladder Cancer in High Risk Carcinoma in Situ Disease Earn FDA Breakthrough Status for ImmunityBio’s IL-15 Superagonist Complex CULVER CITY, Calif., Dec. 4, 2019 - ImmunityBio, a...
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety Culver City, Calif., Nov. 7, 2019 – NantKwest Inc. (Nasdaq: NK), a next generation,...
Dr. Soon-Shiong to Launch ImmunityBio, an Immunotherapy Company at Upcoming Jefferies 2019 Annual Healthcare Conference
CULVER CITY, CA. – June 3, 2019 - ImmunityBio , a privately held immunotherapy company at late stage clinical development, that aims to synergistically deploy a broad portfolio of biological molecules as an integrated cancer vaccine platform targeting...
Contact Us
© 2019 ImmunityBio, Inc. All rights reserved.